Terms: = Lymphoma AND FOXO3, FKHRL1, 2309, ENSG00000118689, MGC31925, MGC12739, FOXO2, FOXO3A, O43524, AF6q21, FKHRL1P2, DKFZp781A0677 AND Diagnosis
5 results:
1. Noncanonical β-catenin interactions promote leukemia-initiating activity in early T-cell acute lymphoblastic leukemia.
Panelli P; De Santis E; Colucci M; Tamiro F; Sansico F; Miroballo M; Murgo E; Padovano C; Gusscott S; Ciavarella M; Chavez EA; Bianchi F; Rossi G; Carella AM; Steidl C; Weng AP; Giambra V
Blood; 2023 Mar; 141(13):1597-1609. PubMed ID: 36315912
[TBL] [Abstract] [Full Text] [Related]
2. foxo3a and Posttranslational Modifications Mediate Glucocorticoid Sensitivity in B-ALL.
Consolaro F; Ghaem-Maghami S; Bortolozzi R; Zona S; Khongkow M; Basso G; Viola G; Lam EW
Mol Cancer Res; 2015 Dec; 13(12):1578-90. PubMed ID: 26376801
[TBL] [Abstract] [Full Text] [Related]
3. A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL.
Han BW; Feng DD; Li ZG; Luo XQ; Zhang H; Li XJ; Zhang XJ; Zheng LL; Zeng CW; Lin KY; Zhang P; Xu L; Chen YQ
Hum Mol Genet; 2011 Dec; 20(24):4903-15. PubMed ID: 21926415
[TBL] [Abstract] [Full Text] [Related]
4. Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker.
Dewar R; Chen ST; Yeckes-Rodin H; Miller K; Khosravi-Far R
Cancer Biol Ther; 2011 Mar; 11(6):552-8. PubMed ID: 21282974
[TBL] [Abstract] [Full Text] [Related]
5. Covert preleukemia driven by MLL gene fusion.
Zuna J; Burjanivova T; Mejstrikova E; Zemanova Z; Muzikova K; Meyer C; Horsley SW; Kearney L; Colman S; Ptoszkova H; Marschalek R; Hrusak O; Stary J; Greaves M; Trka J
Genes Chromosomes Cancer; 2009 Jan; 48(1):98-107. PubMed ID: 18932267
[TBL] [Abstract] [Full Text] [Related]
